Alcobra Ltd. (NASDAQ:ADHD) – Analysts at Jefferies Group increased their FY2017 EPS estimates for Alcobra in a research note issued to investors on Thursday. Jefferies Group analyst B. Amin now anticipates that the firm will post earnings of ($1.00) per share for the year, up from their prior forecast of ($1.07). Jefferies Group currently has a “Buy” rating on the stock. Jefferies Group also issued estimates for Alcobra’s FY2018 earnings at ($0.97) EPS, FY2019 earnings at ($1.09) EPS and FY2020 earnings at ($1.12) EPS.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01.
Several other research firms have also issued reports on ADHD. Cantor Fitzgerald started coverage on Alcobra in a research note on Tuesday, June 7th. They set a “buy” rating and a $16.00 price objective for the company. Canaccord Genuity started coverage on Alcobra in a report on Tuesday, June 7th. They issued a “buy” rating on the stock. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $10.00 price target on shares of Alcobra in a report on Tuesday, August 30th. Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Alcobra in a report on Thursday, September 1st. Finally, WBB Securities cut Alcobra from a “hold” rating to a “sell” rating and reduced their target price for the stock from $5.00 to $4.00 in a report on Monday, September 12th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $6.97.
Shares of Alcobra (NASDAQ:ADHD) opened at 2.47 on Monday. The firm has a 50-day moving average of $4.69 and a 200 day moving average of $4.50. The company’s market capitalization is $68.08 million. Alcobra has a 12 month low of $1.95 and a 12 month high of $8.78.
Hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. increased its stake in Alcobra by 28.2% in the first quarter. Franklin Resources Inc. now owns 3,652,931 shares of the company’s stock worth $13,845,000 after buying an additional 804,350 shares during the last quarter. BlackRock Fund Advisors increased its stake in Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock worth $1,344,000 after buying an additional 36,218 shares during the last quarter. Jefferies Group LLC bought a new stake in Alcobra during the second quarter worth $533,000. VHCP Management II LLC increased its stake in Alcobra by 28.7% in the second quarter. VHCP Management II LLC now owns 1,454,402 shares of the company’s stock worth $6,530,000 after buying an additional 323,902 shares during the last quarter. Finally, VHCP Management LLC increased its stake in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock worth $2,799,000 after buying an additional 138,813 shares during the last quarter. Hedge funds and other institutional investors own 73.69% of the company’s stock.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.